April 11, 2022. In light of the ongoing opioid epidemic, we commend FDA’s goal of fostering the development of non-addictive alternatives to opioids for managing acute pain, and thereby decreasing exposure to opioids and preventing new addiction.
Read More »On Health Policy
NCHR Testimony by Dr. Diana Zuckerman about AMX0035 for ALS at FDA Advisory Committee
March 30, 2022. ALS is a devastating disease and all of us want better treatments to be available as soon as possible. But NCHR agrees with FDA that “The secondary endpoint results are not compelling or supportive of the primary endpoint.”
Read More »NCHR Comments On Transitional Standards for Milk, Whole Grains, and Sodium
March 24, 2022. Nutrition standards that ensure that children receive healthy food alternatives in their school meals are of utmost importance. For this reason, we agree that USDA’s proposed transition standards, which will reduce sodium and increase whole grains, are a much-needed improvement to Child Nutrition Programs.
Read More »NCHR Comments on Statin Use for the Primary Prevention of Cardiovascular Disease
March 21, 2022. We generally agree with the USPSTF’s recommendations for preventive statin use, but suggest several improvements. For example, the studies included in the review varied greatly in the types of patients studied and the outcomes measured, and it seems premature to assume the risks are small, especially since even rare risks can be very serious for some patients. We thus urge the USPSTF to recommend that physicians emphasize other strategies to lower cholesterol, such as changes to lifestyle and diet.
Read More »NCHR Comments on AHRQ’s Review on Schedule of Visits and Televisits for Routine Antenatal Care
March 15, 2022. We agree with the review that the overall assessment of the available evidence is inconclusive regarding the adequacy of a reduced number of antenatal visits or replacing some routine antenatal visits with telehealth appointments.
Read More »